Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800062 | 0.85 | DAGLA (0.36) | JAK3BTKALDH1A1LMNA | |
| SCHEMBL22800150 | 0.84 | KDM4E (0.42) | MAPTJAK3BTKALDH1A1LMNA | |
| SCHEMBL22800170 | 0.83 | KDM4E (0.43) | ALDH1A1LMNATHRB | |
| SCHEMBL22800230 | 0.82 | CYP4F2 (0.39) | MAPTALDH1A1LMNASLC16A3THRA | |
| SCHEMBL22800227 | 0.82 | CYP4F2 (0.39) | MAPTALDH1A1LMNASLC16A3THRA | |
| SCHEMBL22799768 | 0.82 | CYP4F2 (0.39) | MAPTALDH1A1LMNASLC16A3THRA | |
| SCHEMBL22800074 | 0.79 | ICMT (0.35) | MAPTJAK3BTKLMNATDP1 | |
| SCHEMBL22800154 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1LMNATHRB | |
| SCHEMBL22799638 | 0.75 | KDM4E (0.38) | ALDH1A1LMNATHRBTDP1PTPN1 | |
| SCHEMBL20028240 | 0.72 | DCAF1 (0.46) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | MAPT 472/4885JAK3 4749/4885BTK 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.